GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
February 24, 2023 09:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
Acepodia Appoints Thorsten Graef, M.D., Ph.D., as Chief Medical Officer and Michael Brock as Chief Strategy Officer
May 11, 2021 08:00 ET
|
Acepodia USA
SAN MATEO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the appointments...
Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model
November 09, 2018 08:00 ET
|
Nkarta
NK cell potency and persistence significantly improved using cell engineering technology60% increase in cytotoxicity observed with Nkarta NK cells relative to control NK cellsSingle in vivo...
Nkarta Therapeutics Expands Management Team and Establishes New Corporate Headquarters
July 09, 2018 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology From National University of Singapore and St. Jude Children’s Research Hospital
June 11, 2018 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
Nkarta Therapeutics Appoints Veteran Executive Paul Hastings as CEO to Lead Next Phase of Growth
March 01, 2018 14:05 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing natural killer (NK) immune cells to fight cancer, announced that...
Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting
November 03, 2016 16:59 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...